The increase in price target by Stifel suggests a positive outlook on Edwards Lifesciences' stock, potentially leading to increased investor confidence and a short-term positive impact on the stock price. The Hold rating indicates that the stock is currently valued appropriately, but the raised target suggests some upside potential.